Takeda Pharmaceutical Co Ltd - FY2018 Q3 Results Summary
Business Context and Reporting Period
This Form 6-K filing reports the Third Quarter Fiscal Year 2018 (FY2018) results for Takeda Pharmaceutical Company Limited, covering the nine-month period from April 1, 2018, to December 31, 2018. The filing was released on February 1, 2019. A significant corporate event occurred shortly after the reporting period: the acquisition of Shire plc was completed on January 8, 2019. The company is currently integrating Shire and has not yet issued a revised full-year forecast that includes Shire's financial impact, which is expected in April 2019.
Key Financial Metrics (Nine Months Ended Dec 31, 2018)
| Metric | Reported (Bn JPY) | YoY Change | Underlying Growth |
|---|---|---|---|
| Revenue | 1,380.0 | +0.8% | +4.8% |
| Operating Profit | 284.4 | -11.7% | +55.5% (excl. one-time items) |
| Core Earnings | 344.6 | +17.7% | +32.3% |
| Net Profit | 164.4 | -31.7% | N/A |
| Earnings Per Share (EPS) | 210 JPY | -32.0% | +34.2% (Underlying Core EPS) |
| Operating Free Cash Flow | 121.4 | -20.2% | N/A |
Balance Sheet Highlights: Total assets increased to 5,767.2 billion JPY. Total debt (Bonds and Loans) rose to 2,548.8 billion JPY, primarily due to financing for the Shire acquisition. The Net Debt/Adjusted EBITDA ratio (including cash in escrow) stood at 1.6x.
Material Changes vs. Prior Period
- Revenue: Reported revenue growth was muted at +0.8% due to a -3.0 percentage point impact from divestitures (including sales to Teva JV, Multilab, and Techpool) and a -1.1 percentage point impact from foreign exchange rates. Underlying revenue grew +4.8%, driven by strong performance in Growth Drivers (Gastroenterology, Oncology, Neuroscience, and Emerging Markets), which grew +10.5%.
- Profitability: Reported Operating Profit declined -11.7% primarily due to the absence of large one-time gains recorded in FY2017 (sale of Wako shares and Teva JV products) and the incurrence of Shire-related acquisition costs in FY2018. Excluding these items, Operating Profit grew +55.5%.
- Core Earnings: Underlying Core Earnings grew +32.3% with a margin expansion of 530 basis points. Approximately 70% of this margin improvement was attributed to the Global Opex Initiative.
- Product Performance: Key growth products included Entyvio (+35.1%), Ninlaro (+36.6%), Trintellix (+19.5%), Iclusig (+26.0%), and Alunbrig (+151.4%).
Guidance, Outlook, and Risks
- Guidance: The previously announced full-year FY2018 forecast remains unchanged. Takeda will not issue a revised forecast until April 2019, once the purchase price allocation for the Shire acquisition is finalized and a holistic forecast can be determined.
- Shire Acquisition: The acquisition closed on January 8, 2019. Integration is progressing as planned, with deal financing completed at competitive rates. Rating agencies have confirmed investment-grade credit ratings.
- R&D Milestones: The Phase 3 trial for the dengue vaccine candidate (TAK-003) met its primary efficacy endpoint. Alunbrig received EU approval for post-crizotinib ALK+ NSCLC. The FDA filing for Ninlaro post-transplant maintenance was withdrawn to resubmit with more mature survival data.
- Risks: Key risks include the successful integration of Shire, regulatory approvals for pipeline products, foreign exchange fluctuations, and the impact of divestitures on reported revenue.
Key Facts for Investor Verification
- Verify the reconciliation between Reported and Underlying metrics, as reported results are significantly impacted by one-time gains in the prior year and Shire-related costs in the current year.
- Monitor the April 2019 announcement for the revised full-year guidance that incorporates the Shire acquisition.
- Track the progress of the Shire integration and the realization of synergies.
- Review the status of the Ninlaro resubmission to the FDA and the timeline for the dengue vaccine commercialization.
- Assess the impact of the Global Opex Initiative on future margin expansion.